Page 156 - SAMRC AnnualReport 2025-26

Platform for
Pharmacogenomics

Research and Translation
Research Unit

UNIT DIRECTOR:
Prof. Collet Dandara
collet.dandara@uct.ac.za

Overview of the Research Unit epigenetic determinants of drug response across

infectious and non-communicable diseases, while
The Research Unit is dedicated to identifying
inherited genetic variation, epigenetic modifications, examining how microbial profiles affect therapeutic
and microbial profiles that contribute to differences outcomes, including drug metabolism and efficacy.
Through this work, the Unit generates evidence
in patient responses to therapeutic treatments, to inform clinical dosing guidelines, optimise
including conventional and herbal medicines. The therapeutic interventions, and support healthcare
Unit advances pharmacogenomics research and policy development tailored to African populations.
its clinical translation within African populations
to support the development of personalised, safe, Key Milestones and Achievements
and effective treatment strategies.
During the 2025/2026 financial year, the Platform
Its research focuses on the extensive genomic for Pharmacogenomics Research and Translation
diversity within African populations and how focused primarily on hypertension, preeclampsia,
this influences treatment selection, efficacy, and breast cancer, and chronic kidney disease (CKD),
safety. The Unit also investigates the genetic and resulting in several publications from the Unit.

Activities during Eastern Cape Career Expo.

154 SA M R C A N N U A L R EP O R T 2 0 2 5 / 2 0 2 6